The UK Dementia Research Institute (UK DRI) is a joint £290 million investment into dementia research led by the Medical Research Council (MRC), alongside founding charity partners, the Alzheimer’s Society and Alzheimer’s Research UK.
The UK DRI will deliver a step-change in the scientific understanding of dementia, generating new targets for drug development, reinvigorating the therapeutic pipeline and helping to transform care.
The new national institute will cover dementia across the research spectrum, spanning Alzheimer’s disease, Parkinson’s disease, Frontotemporal dementia, vascular dementia, Huntington’s disease and beyond.
Bringing together over 300 world-leading scientists in biomedical, care and translational dementia research, the institute will carry out a rich, varied and integrated programme of research.
As one of six UK centres, the research centre at Cardiff University will be a significant section of the UK Dementia Research Institute (UK DRI).
The UK DRI will form a vibrant and interactive community, centred on neuroscience working on around 50 five-year research programmes across the UK in order to:
- accelerate the pace of discovery research to identify new targets for drug development
- develop new approaches for delivering effective clinical trials to targeted patient groups
- attract new partnerships with the biopharmaceutical sector to develop new therapeutics and diagnostics
- develop and promote strategies for interventions that prevent the development or progression of dementia
- provide new insights and technology-based approaches to delivering more effective care and support to people with dementia and their carers.
Contact
For general enquiries about the institute please contact: dri@headoffice.mrc.ac.uk or 0207 395 2226.
For press enquiries about the institute please contact: press.office@headoffice.mrc.ac.uk or 020 7395 2274.
